Convenience Claims, Squinty Risk Info For Arbor's Nitro Spray Draw FDA Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Professional sales aid and DTC brochure for Nitrolingual Pumpspray claim the product is superior to tablets without substantial evidence, DDMAC says.
You may also be interested in...
DDMAC Slamming The Door On Open-Label Studies In Promotions
Nycomed gets a "notice of violation" letter for a flashcard that used open-label study data to make claims for its actinic keratoses treatment Solaraze (diclofenac).
DDMAC Slamming The Door On Open-Label Studies In Promotions
Nycomed gets a "notice of violation" letter for a flashcard that used open-label study data to make claims for its actinic keratoses treatment Solaraze (diclofenac).
Convenience Claims Can Put Companies On Slippery Promotional Ground
FDA cites an ad for Sanofi-Aventis' prostate cancer therapy Eligard for implying better patient quality of life and more physician efficiency because of less-frequent injections.